FDA Releases Guidance on Late Radiation Toxicity of Therapeutic Radiopharmaceuticals

Summary

The Food and Drug Administration (FDA) has released a guidance document to help pharmaceutical companies design nonclinical studies to assess the potential late radiation effects of therapeutic radiopharmaceuticals, aiming to minimize the risk of irreversible radiation toxicities in clinical trials.